Replies to post #25485 on Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

Angelo- If you look at the latest presentation on page 30 they say:

1. Anticipate higher revenues Q1 2017 due to 25 and 35 mg launch of generic Focalin XR®

Any additional revenue that would appear on IPCI's 1st Qtr filing would have to be from a Milestone payment... of which we're still not sure of... but they are certainly not getting any royalty money... YET.

2. Additional revenues from Endo (PAR) launch of generic Focalin®XR 5, 10, 20, 40mg strengths

That won't happen as they have not yet launched those doses... unless they have launched and not PR'ed it.

p.s. the way I read it.... we are entitled to a milestone payment on the launch of the 25mg and 35mg as they have paragraph 4 exclusivity... I don't believe it applied only to the 15mg and 30mg... just my interpretation of the agreement.